Roetzheim R G, Herold A H
Department of Family Medicine, University of South Florida, Tampa.
Prim Care. 1992 Sep;19(3):637-49.
No screening test has been proven to reduce prostate cancer mortality. DRE has been the traditional method of screening, and it is often used to detect other diseases in addition to prostate cancer. Newer modalities, such as TRUS and PSA, can identify patients with nonpalpable prostate cancer, but the use of these tests will also result in many false-positives. In addition, it is not known whether the use of these tests will reduce prostate cancer mortality, or instead cause harm to those patients screened. Given the potential for harm, and the extraordinary expense, routine screening of asymptomatic men with newer modalities should be considered experimental.
尚无筛查试验被证明可降低前列腺癌死亡率。直肠指检（DRE）一直是传统的筛查方法，除前列腺癌外，它还常用于检测其他疾病。较新的检查手段，如经直肠超声检查（TRUS）和前列腺特异抗原（PSA），可识别出不可触及的前列腺癌患者，但这些检查也会导致许多假阳性结果。此外，尚不清楚使用这些检查是否会降低前列腺癌死亡率，还是反而会对接受筛查的患者造成伤害。鉴于存在潜在危害以及费用高昂，对于无症状男性使用较新检查手段进行常规筛查应被视为试验性的。
